Want to join the conversation?
$AGN said the company continues to expect FY16 net revenues to be approx. $17Bil, including branded business revenue of about $15Bil. GM is expected to remain strong with no material change from current levels in each segment. R&D expense is expected to be about $1.5Bil, as a result of the many late stage programs advancing in the pipeline.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.